# Exploring the Theragnostic Value of Osimertinib in EGFR-mutated Lung Cancer (THEROS)

> **NCT03810066** · PHASE2 · COMPLETED · sponsor: **University Hospital, Essen** · enrollment: 16 (actual)

## Conditions studied

- NSCLC
- EGFR T790M
- FDG-PET

## Interventions

- **DRUG:** Osimertinib

## Key facts

- **NCT ID:** NCT03810066
- **Lead sponsor:** University Hospital, Essen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-03
- **Primary completion:** 2021-12-31
- **Final completion:** 2022-09-30
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2024-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03810066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03810066, "Exploring the Theragnostic Value of Osimertinib in EGFR-mutated Lung Cancer (THEROS)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03810066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*